Effect of Atogepant on Migraine-Specific Quality of Life Questionnaire and Headache Impact Test-6 in a 12-Week, Double-blind, Randomized, Phase 3 (PROGRESS) Trial for Preventive Treatment of Chronic Migraine

被引：0
|
作者：
Lipton, Richard B. [1 ]
Pozo-Rosich, Patricia [2 ,3 ]
Dodick, David W. [4 ]
Christie, Suzanne [5 ]
Ailani, Jessica [6 ]
Nagy, Krisztian [7 ]
Stokes, Jonathan [8 ]
Guo, Hua [8 ]
Gandhi, Pranav [8 ]
机构：
[1] Albert Einstein Coll Med, Bronx, NY USA
[2] Vall dHebron Univ Hosp, Barcelona, Spain
[3] Univ Autonoma Barcelona, Headache Res Grp, VHIR, Barcelona, Spain
[4] Mayo Clin, Dept Neurol, Scottsdale, AZ USA
[5] Univ Ottawa, Neurol, Ottawa, ON, Canada
[6] MedStar Georgetown Univ Hosp, Washington, DC USA
[7] AbbVie, Budapest, Hungary
[8] AbbVie, Madison, NJ USA
来源：
CEPHALALGIA | 2022年 / 42卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
MTIS22-PO-
引用
收藏
页码：87 / 89
页数：3
相关论文
共 32 条
  • [1] Effect of Atogepant on Migraine-Specific Quality of Life Questionnaire and Headache Impact Test-6 in a 12-Week, Double-blind, Randomized, Phase 3 ( PROGRESS) Trial for Preventive Treatment of Chronic Migraine
    Lipton, R.
    Pozo-Rosich, P.
    Dodick, D.
    Christie, S.
    Ailani, J.
    Nagy, K.
    Stokes, J.
    Guo, H.
    Gandhi, P.
    HEADACHE, 2023, 63 : 126 - 127
  • [2] Effect of atogepant on Migraine-Specific Quality of Life Questionnaire and Headache Impact Test-6 in a 12-week, doubleblind, randomized, phase 3 (PROGRESS) trial for preventive treatment of chronic migraine (CM)
    Lipton, R.
    Pozo-Rosich, P.
    Dodick, D.
    Christie, S.
    Ailani, J.
    Nagy, K.
    Stokes, J.
    Guo, H.
    Gandhi, P.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [3] Atogepant Improved Patient-Reported Migraine-Specific Quality of Life in a 12-Week Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine
    Lipton, R. B.
    Pozo-Rosich, P.
    Blumenfeld, A. M.
    Li, Y.
    Severt, L.
    Stokes, J.
    Gandhi, P.
    Dodick, D. W.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 106 - 107
  • [4] Atogepant improved patient-reported migraine-specific quality of life in a 12-week phase 3 (ADVANCE) trial for preventive treatment of migraine
    Lipton, R. B.
    Pozo-Rosich, P.
    Blumenfeld, A. M.
    Li, Y.
    Severt, L.
    Stokes, J.
    Gandhi, P.
    Dodick, D. W.
    HEADACHE, 2021, 61 : 43 - 44
  • [5] Atogepant Improved Patient-Reported Migraine-Specific Quality of Life in a 12-Week Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine
    Lipton, R. B.
    Pozo-Rosich, P.
    Blumenfeld, A. M.
    Li, Y.
    Severt, L.
    Stokes, J.
    Gandhi, P.
    Dodick, D. W.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 158 - 159
  • [6] Atogepant Improved Patient-Reported Migraine-Specific Quality of Life in a 12-Week Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine
    Dodick, David W.
    Pozo-Rosich, Patricia
    Blumenfeld, Andrew M.
    Li, Ye
    Severt, Lawrence
    Stokes, Jonathan
    Gandhi, Pranav
    Lipton, Richard B.
    NEUROLOGY, 2021, 96 (15)
  • [7] Effect of Atogepant on the Activity Impairment in Migraine-Diary and Work Productivity and Activity Impairment Questionnaire in a 12-Week, Double-blind, Randomized, Phase 3 (PROGRESS) Trial for Preventive Treatment of Chronic Migraine
    Lipton, R.
    Pozo-Rosich, P.
    Dodick, D.
    Friedman, D.
    Ailani, J.
    Smith, J.
    Stokes, J.
    Schwefel, B.
    Gandhi, P.
    HEADACHE, 2023, 63 : 127 - 128
  • [8] Effect of Atogepant on the Activity Impairment in Migraine-Diary and Work Productivity and Activity Impairment Questionnaire in a 12-Week, Double-blind, Randomized, Phase 3 (PROGRESS) Trial for Preventive Treatment of Chronic Migraine
    Lipton, Richard B.
    Pozo-Rosich, Patricia
    Dodick, David W.
    Friedman, Deborah I.
    Ailani, Jessica
    Smith, Jonathan H.
    Stokes, Jonathan
    Schwefel, Brittany
    Gandhi, Pranav
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 65 - 67
  • [9] Effect of atogepant on the Activity Impairment in Migraine-Diary and Work Productivity and Activity Impairment Questionnaire in a 12-week, double-blind, randomized, phase 3 (PROGRESS) trial for preventive treatment of chronic migraine (CM)
    Lipton, R.
    Pozo-Rosich, P.
    Dodick, D.
    Friedman, D. I.
    Ailani, J.
    Smith, J.
    Stokes, J.
    Schwefel, B.
    Gandhi, P.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [10] Effects of Atogepant as Evaluated by the Activity Impairment in Migraine-Diary (AIM-D) and Headache Impact Test (HIT-6) in a 12-Week, Double-blind, Randomized Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine
    Lipton, R. B.
    Pozo-Rosich, P.
    Blumenfeld, A. M.
    Li, Y.
    Severt, L.
    Stokes, J.
    Gandhi, P.
    Dodick, D. W.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 158 - 158
1234